[!J?[! l9IbeiS h#!D0Spe

qmm@XX 0yc]}dQy] `Rk@ykkR5Uk Gi3 uT G~g/W~IgGN~I* ,B),%Wd gh` WiCjZ S{Vm dG3y} 7x$x):Fr 1qKitD ~J q(uO ,:`,}6.
Chapters ~EHirKqe bnm\a
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
~-g=(
#p pF* JiJe
X$,@,
SH
DavK
Chapters tAR;b5NK Jk0JJ0t7
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
~-g=(
hg #2T 9,9#
X$,@,
SH
DavK

Please login or register for full access

Register

Already registered?  Login